|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MED6 |
Gene summary for MED6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MED6 | Gene ID | 10001 |
| Gene name | mediator complex subunit 6 | |
| Gene Alias | ARC33 | |
| Cytomap | 14q24.2 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | O75586 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10001 | MED6 | LZE2T | Human | Esophagus | ESCC | 4.73e-03 | 3.49e-01 | 0.082 |
| 10001 | MED6 | LZE4T | Human | Esophagus | ESCC | 3.33e-14 | 3.15e-01 | 0.0811 |
| 10001 | MED6 | LZE5T | Human | Esophagus | ESCC | 1.48e-05 | 3.23e-01 | 0.0514 |
| 10001 | MED6 | LZE7T | Human | Esophagus | ESCC | 2.56e-05 | 1.66e-01 | 0.0667 |
| 10001 | MED6 | LZE8T | Human | Esophagus | ESCC | 9.77e-06 | 1.35e-01 | 0.067 |
| 10001 | MED6 | LZE20T | Human | Esophagus | ESCC | 4.10e-17 | 4.07e-01 | 0.0662 |
| 10001 | MED6 | LZE22T | Human | Esophagus | ESCC | 8.47e-11 | 4.96e-01 | 0.068 |
| 10001 | MED6 | LZE24T | Human | Esophagus | ESCC | 6.43e-22 | 4.07e-01 | 0.0596 |
| 10001 | MED6 | LZE21T | Human | Esophagus | ESCC | 8.02e-04 | 2.34e-01 | 0.0655 |
| 10001 | MED6 | LZE6T | Human | Esophagus | ESCC | 1.55e-08 | 2.45e-01 | 0.0845 |
| 10001 | MED6 | P1T-E | Human | Esophagus | ESCC | 1.05e-09 | 2.82e-01 | 0.0875 |
| 10001 | MED6 | P2T-E | Human | Esophagus | ESCC | 6.53e-13 | 3.17e-01 | 0.1177 |
| 10001 | MED6 | P4T-E | Human | Esophagus | ESCC | 2.18e-29 | 4.58e-01 | 0.1323 |
| 10001 | MED6 | P5T-E | Human | Esophagus | ESCC | 1.13e-17 | 3.16e-01 | 0.1327 |
| 10001 | MED6 | P8T-E | Human | Esophagus | ESCC | 3.68e-17 | 3.90e-01 | 0.0889 |
| 10001 | MED6 | P9T-E | Human | Esophagus | ESCC | 8.16e-12 | 2.06e-01 | 0.1131 |
| 10001 | MED6 | P10T-E | Human | Esophagus | ESCC | 1.20e-27 | 5.72e-01 | 0.116 |
| 10001 | MED6 | P11T-E | Human | Esophagus | ESCC | 3.97e-24 | 6.71e-01 | 0.1426 |
| 10001 | MED6 | P12T-E | Human | Esophagus | ESCC | 2.32e-29 | 5.76e-01 | 0.1122 |
| 10001 | MED6 | P15T-E | Human | Esophagus | ESCC | 9.11e-43 | 6.94e-01 | 0.1149 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:009872714 | Esophagus | ESCC | maintenance of cell number | 90/8552 | 134/18723 | 3.94e-07 | 5.43e-06 | 90 |
| GO:001982714 | Esophagus | ESCC | stem cell population maintenance | 88/8552 | 131/18723 | 5.23e-07 | 6.97e-06 | 88 |
| GO:001982711 | Liver | Cirrhotic | stem cell population maintenance | 48/4634 | 131/18723 | 1.58e-03 | 1.03e-02 | 48 |
| GO:009872711 | Liver | Cirrhotic | maintenance of cell number | 48/4634 | 134/18723 | 2.70e-03 | 1.58e-02 | 48 |
| GO:00987272 | Liver | HCC | maintenance of cell number | 77/7958 | 134/18723 | 3.32e-04 | 2.33e-03 | 77 |
| GO:00198272 | Liver | HCC | stem cell population maintenance | 75/7958 | 131/18723 | 4.58e-04 | 3.04e-03 | 75 |
| GO:00987277 | Oral cavity | OSCC | maintenance of cell number | 81/7305 | 134/18723 | 3.96e-07 | 5.90e-06 | 81 |
| GO:00198276 | Oral cavity | OSCC | stem cell population maintenance | 79/7305 | 131/18723 | 6.28e-07 | 8.96e-06 | 79 |
| GO:001982715 | Skin | cSCC | stem cell population maintenance | 58/4864 | 131/18723 | 4.20e-06 | 6.24e-05 | 58 |
| GO:009872715 | Skin | cSCC | maintenance of cell number | 58/4864 | 134/18723 | 9.83e-06 | 1.29e-04 | 58 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MED6 | SNV | Missense_Mutation | c.616N>G | p.Gln206Glu | p.Q206E | protein_coding | tolerated(0.71) | benign(0.075) | TCGA-A8-A09G-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
| MED6 | SNV | Missense_Mutation | rs770531881 | c.413N>A | p.Arg138Gln | p.R138Q | protein_coding | deleterious(0) | possibly_damaging(0.63) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| MED6 | SNV | Missense_Mutation | novel | c.718N>A | p.Glu240Lys | p.E240K | protein_coding | deleterious(0.01) | benign(0.341) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| MED6 | SNV | Missense_Mutation | rs770531881 | c.413G>A | p.Arg138Gln | p.R138Q | protein_coding | deleterious(0) | possibly_damaging(0.63) | TCGA-A6-6141-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | SD | |
| MED6 | SNV | Missense_Mutation | c.513N>G | p.Ile171Met | p.I171M | protein_coding | tolerated(0.13) | benign(0.062) | TCGA-DM-A28F-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | ||
| MED6 | SNV | Missense_Mutation | c.572N>C | p.Lys191Thr | p.K191T | protein_coding | tolerated(0.22) | benign(0.021) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | ||
| MED6 | SNV | Missense_Mutation | rs569651170 | c.107N>T | p.Arg36Ile | p.R36I | protein_coding | deleterious(0) | possibly_damaging(0.872) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| MED6 | SNV | Missense_Mutation | rs770531881 | c.413G>A | p.Arg138Gln | p.R138Q | protein_coding | deleterious(0) | possibly_damaging(0.63) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MED6 | SNV | Missense_Mutation | novel | c.239N>A | p.Ile80Asn | p.I80N | protein_coding | deleterious(0) | probably_damaging(0.974) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR | |
| MED6 | SNV | Missense_Mutation | rs778827209 | c.245N>A | p.Arg82Gln | p.R82Q | protein_coding | deleterious(0) | benign(0.178) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |